



QUIDEL

# MicroVue™ Complement

CIC-C1q EIA

For the detection of immune complexes in human serum or plasma.


**R<sub>x</sub> ONLY**

## SUMMARY

### Reagent and Sample Preparation

- Dilute Wash Solution Concentrate 1:20 with DI Water
- Reconstitue each Standard with 2.0 mL of Hydrating Reagent, mix thoroughly, and let sit for 15 minutes. (Stable for 30 days)
- Dilute Samples 1:50 with Complement Specimen Diluent (10  $\mu$ L + 490  $\mu$ L)

### Assay Procedure





## INTENDED USE

The MicroVue CIC-C1q EIA is designed for the detection of immune complexes in human serum or plasma.

### SUMMARY AND EXPLANATION

The importance of circulating immune complexes (CIC) and their relationship to various diseases has been the subject of investigation for a number of years. Formation of immune complexes is a protective, ongoing, and usually benign, process of a normally functioning immune system. CIC are removed from the circulation in the normal host by a number of complex biochemical, enzymatic, and cellular processes. Key to the elimination of many CIC is the activation of the classical complement pathway.

However, under certain disease conditions that are still poorly understood, immune complexes may initiate complement-dependent injury of various organs and tissues. This activation of complement may begin a series of potentially destructive events in the host including anaphylatoxin production, cell lysis, leukocyte stimulation, and activation of macrophages and other cells.<sup>1</sup> When immune complexes become fixed to vessel walls or cell membranes, destruction of normal tissue can occur, as in some cases of glomerulonephritis. Certain properties of CIC influence their potential pathogenicity.

Of particular importance are: (1) nature, size and concentration of the antigen; (2) nature, size and concentration of the antibody; and, (3) rate of formation and clearance of the immune complexes.<sup>1,2</sup> Circulating immune complexes have been measured in a variety of conditions: infections, autoimmune disorders, trauma, and neoplastic proliferative diseases. Current studies suggest that CIC determination can be important in the evaluation of certain diseases and, sometimes, in monitoring efficiency of therapy. This is especially true in systemic lupus erythematosus (SLE) and some forms of rheumatoid arthritis (RA).<sup>3,4</sup> Classically, the first disease state linked to the formation of immune complexes was serum sickness, described in the early 1900's by von Pirquet. Since that time elevated levels of CIC have been described in autoimmune diseases (SLE, SLE-related syndrome, RA), glomerulonephritis, neoplastic disease (Hodgkin's, leukemia), bacterial infections (subacute bacterial endocarditis [SBE], leprosy), parasitic infections (malaria, schistosomiasis) and viral infections (hepatitis, mononucleosis).

Over 40 assay techniques have been described to detect or quantitate CIC. Such tests as the Raji Cell assay, C1q deviation test, conglutinin test, fluid phase C1q binding procedures, rheumatoid factor assay, PEG precipitin test, and solid phase C1q assays have been described.<sup>1,5</sup> Since the size and physiochemical properties of CIC vary markedly, none of these assays has been accepted as a standard. A collaborative study sponsored by the World Health Organization in 1978 determined that no single method was appropriate in all suspected disease states and recommended that at least two different assay techniques be performed to detect and measure CIC adequately.

### PRINCIPLE OF THE PROCEDURE

The MicroVue CIC-C1q EIA is based on the principle that complement fixing CIC will bind to immobilized human C1q purified protein.

In the first stage, standards and serum or plasma specimens diluted in Complement Specimen Diluent are added to the C1q-coated microtiter wells and incubated. During this incubation period, immune complexes that bind to C1q will complex with the C1q-coated microassay wells. To confirm a positive CIC result, the specimen may be diluted in Confirmation Diluent, which contains a high salt concentration known to inhibit the binding of CIC to C1q,<sup>6,7</sup> and then added to the microtiter wells and incubated. A wash cycle removes unbound serum proteins.

In the second stage, horseradish peroxidase (HRP)-conjugated goat anti-human IgG is added to each test well. During this incubation, the conjugate will bind to the immune complexes that are now bound to the C1q-coated microassay wells. A wash cycle removes unbound conjugate.

In the third stage, an enzyme substrate is added to each test well. The bound HRP-conjugated antibody reacts with the chromogenic substrate forming a green color. After incubation, a reagent is added to stop color development.

The standard and test specimen absorbances ( $A_{405}$  values) are measured spectrophotometrically. The intensity of the green color is proportional to the amount of CIC IgG antibodies binding the solid-phase C1q. A standard curve is generated by plotting the  $A_{405}$  values obtained with each standard versus its concentration. The concentration of immune complexes present in the test specimen is determined by reference to the standard curve. Results are expressed as heat aggregated human gamma globulin equivalents per mL ( $\mu\text{g Eq/mL}$ ).

## REAGENTS AND MATERIALS PROVIDED

The CIC-C1q EIA kit contains the following:

<b>A</b>	<b>CIC-C1q Standards</b>	<b>Parts A9503-A9505</b>	<b>2 each, 2 mL</b>
<b>B</b>	(lyophilized) When reconstituted, each contains a known quantity of heat aggregated human gamma		
<b>C</b>	globulin (HAGG), in PBS, 2.5% stabilizers		
<b>1</b>	<b>Microassay Plate</b>	<b>Part A9500</b>	<b>12 each</b>
	96-well with retainer and holder consisting of eight-well strips coated with purified human C1q protein in a resealable foil pouch.		
<b>2</b>	<b>Stop Solution</b>	<b>Part A3673</b>	<b>6 mL</b>
	Contains 250 mM oxalic acid		
<b>3</b>	<b>20X Wash Solution Concentrate</b>	<b>Part A9957</b>	<b>2 each, 50 mL</b>
	Each contains phosphate buffered saline (PBS), 1.0% Tween-20®, and 0.035% ProClin® 300		
<b>4</b>	<b>Complement Specimen Diluent</b>	<b>Part A3670</b>	<b>50 mL</b>
	Contains PBS, 0.05% Tween-20, 2.5% stabilizers, 0.035% ProClin 300		
<b>5</b>	<b>Substrate Diluent</b>	<b>Part A3672</b>	<b>25 mL</b>
	Contains 0.1M citrate buffer and 0.05% H <sub>2</sub> O <sub>2</sub>		
<b>6</b>	<b>Substrate Concentrate</b>	<b>Part A3671</b>	<b>1.5 mL</b>
	Contains 0.7% 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid), diammonium salt		
<b>7</b>	<b>CIC-C1q Conjugate</b>	<b>Part A9506</b>	<b>2 each, 3 mL</b>
	Peroxidase-conjugated (goat) anti-human IgG suspended in HRP stabilizing buffer		
<b>8</b>	<b>Hydrating Reagent</b>	<b>Part A3675</b>	<b>25 mL</b>
	Contains 0.035% ProClin 300		
<b>9</b>	<b>Confirmation Diluent</b>	<b>Part A9511</b>	<b>2 each, 10 mL</b>
	Contains PBS, 2.5% stabilizers, 1.2 M NaCl, 0.035% ProClin 300		

## MATERIALS REQUIRED BUT NOT PROVIDED

- Timer (60 minute range)
- Calculator or other computational method to validate the assay
- Clean, unused microassay plates and/or test tubes and racks
- Container for wash buffer dilution
- Wash bottle or other immunoassay washing system
- Adjustable multichannel pipette (8 or 12 channels) or repeating micropipettes (optional)
- Clean pipettes, 1 mL, 5 mL, and 10 mL
- Micropipettes and pipette tips
- Plate reader capable of optical density  $A_{405}$  readings between 0.0 and 2.0
- Deionized or distilled water

## WARNINGS AND PRECAUTIONS

- For *in vitro* diagnostic use.
- Treat specimen samples as potentially biohazardous material. Follow Universal Precautions when handling contents of this kit and any patient samples.
- Dispose of containers and unused contents in accordance with Federal, State and Local regulations.
- Use the supplied reagents as an integral unit prior to the expiration date indicated on the package label.
- Wear suitable protective clothing, gloves, and eye/face protection when handling contents of this kit.
- Store assay reagents as indicated.
- Do not use Coated Strips if pouch is punctured.
- Test each sample in duplicate.
- ProClin 300 is used as a preservative. Incidental contact with or ingestion of buffers or reagents containing ProClin can cause irritation to the skin, eyes or mouth. Use good laboratory practices to reduce exposure. Seek medical attention if symptoms are experienced.
- Use of multichannel pipettes or repeat pipettors is recommended to ensure timely delivery of reagents.
- For accurate measurement of samples, add samples and standards precisely. Pipette carefully using only calibrated equipment.
- Proper collection and storage of test specimens are essential for accurate results.
- Avoid microbial or cross-contamination of specimens, reagents, or materials. Incorrect results may be obtained if contaminated.
- Do not use a microassay well for more than one test.
- Decontaminate all specimens, reagents, and materials by soaking for a minimum of 30 minutes in a 1:10 solution of household bleach (sodium hypochlorite) or autoclave at 121°C for 30 minutes at 15 psi.
- Using incubation times and temperatures other than those indicated in the Procedure section may give erroneous results.
- The Substrate Concentrate is light sensitive. Avoid prolonged exposure to bright or direct light. Store reagents in the dark when not in use.
- Do not allow microassay wells to dry once the assay has begun.
- When adding or aspirating liquids from the microassay wells, do not scrape or touch the bottom of the wells.
- Heat-inactivated, hyperlipemic or contaminated specimens may give erroneous results.
- To avoid aerosol formation during washing, use an apparatus to aspirate the wash fluid into a bottle containing household bleach.
- This assay may be performed with any validated washing method.
- Wash hands thoroughly after handling.
- For additional information on hazard symbols, safety, handling and disposal of the components within this kit, please refer to the Safety Data Sheet (SDS) located at [quidel.com](http://quidel.com).

## STORAGE

Store unopened kit at 2°C to 8°C. After the kit is opened, the 20X Wash Solution Concentrate and Hydrating Reagent may be store at 2°C to 30°C.

After selecting the reagents or materials to be used in the assay, return the unused reagents immediately to their appropriate storage temperatures. Bring reagents and materials to room temperature (15°C to 30°C) before use.

## INDICATIONS OF INSTABILITY OR DETERIORATION OF REAGENTS

The Substrate Concentrate may range in color from colorless to pale or dark green. This condition will not influence performance. However, the freshly prepared Substrate Solution should be colorless to pale green. A dark green color indicates that the prepared Substrate Solution has deteriorated, must be discarded, and new Substrate Solution prepared in clean glassware.

Cloudiness or discoloration of the diluted Wash Solution indicates a deterioration of this reagent. If this occurs, the solution should be discarded.

## SPECIMEN COLLECTION AND STORAGE

### **Handle and dispose of all specimens using Universal Precautions.**

The assay requires at least 10 µL of serum or EDTA plasma. All specimens should be collected aseptically and prepared using standard techniques for clinical laboratory testing.<sup>9</sup> Do not heat-inactivate the specimens. Any particulate matter should be cleared from the specimens by low speed centrifugation before testing.

Samples may be stored at 2°C to 8°C for up to 7 days. If specimens are stored for longer periods, they should be frozen at –20°C or below, in a freezer which is not self-defrosting.

## REAGENT PREPARATION

Refer to Table 1 for the amounts of Substrate Solution and microassay strips required per number of tests. After removing the needed reagents and materials, return the unused items to their appropriate storage temperatures (see *STORAGE*). **Bring all reagents and materials for the assay to room temperature (15°C to 30°C) before using.**

### 1. **Wash Solution**

Mix the 20X Wash Solution Concentrate by inverting the bottle several times. If the 20X Wash Solution Concentrate has been stored at 2°C to 8°C, crystals may have formed. To dissolve the crystals, warm the bottle in a 37°C to 50°C water bath until all crystals have dissolved. Mix thoroughly. Prepare the Wash Solution for washing the microassay wells by diluting the entire contents of one of the bottles of 20X Wash Solution Concentrate up to one liter with distilled or deionized water. Mix thoroughly. The Wash Solution is stable for 30 days when stored in a clean container at 2°C to 8°C. If discoloration or cloudiness occurs, discard the reagent.

### 2. **Selecting the Microassay Strips**

Remove the strip retainer from the assembled plate. Determine the number of strips required for the assay by referring to Table 1. Remove the unneeded strips and place them in the storage bag, reseal the bag, and return to storage at 2°C to 8°C. Secure the strips to be used in the assay by replacing the strip retainer securely onto the microassay plate.

### 3. **CIC-C1q Standard Reconstitution**

Add 2.0 mL Hydrating Reagent to standard vials, A-C. Allow lyophilized standards to rehydrate for at least 15 minutes, followed by thorough mixing. Avoid formation of foam or bubbles during mixing. Reconstituted standards are stable for 30 days when stored at 2°C to 8°C.

### 4. **Specimen Dilution**

**Caution: Treat all specimens as if potentially infectious. Do not use heat-inactivated or contaminated specimens.** Determine the number (N) of specimens to be tested. Label test tubes #1 through #N and record which specimen will correspond to each tube on the data sheet provided. Prepare a 1-to-50 dilution of each specimen using the Complement Specimen Diluent (e.g., 10 µL test specimen mixed with 490 µL Complement Specimen Diluent). Mix thoroughly, but avoid formation of foam and bubbles. Do not store or re-use diluted specimens. If the measured concentration of immune complexes in a sample is greater than the concentration of Standard C and a more accurate end point result is desired, repeat testing of the specimen at a 1:200 dilution (fourfold dilution of the 1:50 dilution) is recommended. Note: Specimens that have measured concentrations of CIC less than Standard C should not be diluted further and retested.

### 5. **Adding diluted specimens to the microassay wells**

Either of two methods can be used to add your diluted specimens, standards, controls and buffer to the wells. See Step 3 of Assay Procedure. For small assay runs where only a few specimens are being tested, the diluted specimens and other reagents can be added directly to their assigned well with a micropipette (100 µL/well). For small or large runs, but especially larger runs, we recommend the use of a multi-channel pipettor for adding specimens as follows. **(This latter procedure may be used to conveniently add the conjugate, substrate and stop solution as well.)**

In order to load the standards, controls and diluted specimens into the microassay wells as rapidly as possible, a “replica plating” procedure can be employed. Instead of adding 100 µL of each standard, control or diluted specimen to the C1q coated wells individually, 120-130 µL of each solution can be added to individual wells in a blank plate (not provided) corresponding to the final EIA pattern desired. After all the solutions to be tested have been added to the microassay wells in the blank plate, rapidly transfer 100 µL from each blank well to the C1q coated wells using a multi-channel micropipettor. To avoid the possibility of cross-contamination, pipette tips must be changed each time there is a change in the composition of the samples to be transferred.

### 6. **Confirmation Dilution (optional)**

If confirmation is desired, determine the number (N) of specimens to be confirmed. Label test tubes #1c through #Nc and record which specimens will correspond to each tube on the provided data sheet. Prepare the appropriate dilution (1:50 or 1:200) using the Confirmation Diluent. A specimen diluted in Confirmation Diluent must be run concurrently with the same dilution of specimen in Complement Specimen Diluent.

### 7. **Preparation of Substrate Solution**

Prepare just prior to use. Determine the required volume of Substrate Solution from Table 1. Prepare the Substrate Solution by adding 50 µL of Substrate Concentrate per mL of Substrate Diluent. Mix thoroughly.

**Table 1**  
**Assay requirements**

<b>Wells<sup>1</sup></b>	<b>8-Well Strips</b>	<b>Substrate Solution Required (mL)</b>	<b>Substrate Diluent (mL)</b>	<b>Substrate Concentrate (µL)</b>
16	2	1.6	2.0	100
24	3	2.4	3.0	150
32	4	3.2	4.0	200
40	5	4.0	5.0	250
48	6	4.8	5.0	250
56	7	5.6	6.0	300
64	8	6.4	7.0	350
72	9	7.2	8.0	400
80	10	8.0	9.0	450
88	11	8.8	9.0	450
96	12	9.6	10.0	500

<sup>1</sup>Determine the number of specimens to be tested and add seven (7) wells for the three standards (to be tested in duplicate) and one blank well. It is recommended that duplicate standards be tested in separate microassay strips when possible.

## ASSAY PROCEDURE

**Read entire product insert before beginning the assay.**

See *REAGENT PREPARATION* before proceeding. Grip the plate firmly during all handling to prevent accidental removal of the strip retainer.

1. Record the well positions corresponding to all test samples and standards, as well as the indicated lot number from the vial labels. Label one corner of the Microassay Plate for orientation.
2. Prepare the microassay strips as follows:
  - a. Rehydrate microassay wells by adding approximately 300 µL of Wash Solution to each well using a wash bottle or automated plate-washing device.
  - b. Incubate at room temperature (15°C to 30°C) for 15 to 20 minutes.
  - c. Remove the fluid from the wells.
  - d. Invert the plate and tap firmly on absorbent paper twice to remove any remaining fluid. **Do not allow the wells to dry.**
3. Add 100 µL of Complement Specimen Diluent to the well(s) that will be used to blank the plate reader.
4. Add 100 µL of each reconstituted CIC-C1q Standard (A, B, C,) to duplicate wells.
5. Add 100 µL of each diluted specimen to its assigned microassay well. See *REAGENT PREPARATION*, item 5.
6. Incubate at room temperature (15°C to 30°C) for 60 ± 1 minutes.
7. Wash the microassay wells as follows:
 

**Note: The microassay well-washing procedure can be done manually or with an automated plate washer.**

  - a. After the incubation in step 6 (and in step 9 below), remove the contents from each well.
  - b. Add approximately 300 µL Wash Solution to each well using a wash bottle or automated plate-washing device.
  - c. Incubate the wells for 1 minute at room temperature (15°C to 30°C).
  - d. Remove the contents from each well.
  - e. Add approximately 300 µL Wash Solution to each well.
  - f. Remove the contents from each well.
  - g. **Repeat steps e-f three additional times.**
  - h. After this fifth wash cycle, invert the plate and tap firmly on absorbent paper twice to remove any remaining liquid.

8. Using a multi-channel or repeating pipette, dispense 50  $\mu\text{L}$  of the Conjugate into each washed test well, including the blank well(s).
9. Incubate the microassay strips at room temperature (15°C to 30°C) for  $30 \pm 1$  minutes. Prepare the Substrate Solution during this incubation (see *REAGENT PREPARATION*, item 8).
10. Wash the microassay wells after the 30-minute incubation (step 9), as described under *ASSAY PROCEDURE*, step 7.
11. Immediately following the wash procedure, dispense 100  $\mu\text{L}$  of the freshly prepared Substrate Solution into each well, including the blanks.
12. Incubate the microassay strips at room temperature (15°C to 30°C) for  $30 \pm 1$  minutes.
13. Add 50  $\mu\text{L}$  of Stop Solution to each well to stop the enzymatic reaction. The Stop Solution should be added to the wells in the same order and at the same rate as was the Substrate Solution. Gently tap the plate to evenly disperse the color.
14. Determine the absorbance reading at 405 nm for each test well within one hour after the addition of the Stop Solution (step 13), making a blank correction in accordance with the spectrophotometric system in use.
15. Dispose of the remaining diluted specimens, substrate, and the used microassay strips (see *WARNINGS AND PRECAUTIONS*, item 3).

## RECOMMENDED CONFIRMATION METHOD

If independent confirmation of a positive result is required, or if a positive result is inconsistent with the clinical interpretation, the positive specimen may be assayed using a confirmation test. A negative result cannot be confirmed. The confirmation method utilizes a specimen diluent (the Confirmation Diluent), which contains a high concentration of sodium chloride.<sup>6,7</sup> To confirm a positive result, an aliquot of the specimen must be diluted (1:50 or 1:200) in the Confirmation Diluent and a second aliquot diluted similarly in the Complement Specimen Diluent. Both samples are then assayed according to the usual CIC-C1q assay procedures.

See *REAGENT PREPARATION*, and *INTERPRETATION OF RESULTS* sections for details.

## QUALITY CONTROL

Good laboratory practice recommends that positive and negative controls be included in each assay. Controls for the MicroVue CIC-C1q assay are available from Quidel for this purpose, (CIC-C1q Controls, Catalog #A013), and should be used in accordance with their Package Insert.

In addition to controls, this assay provides a *RECOMMENDED CONFIRMATION METHOD and VALIDATION*.

## INTERPRETATION OF RESULTS

### Calculations

The standard curve is generated using the blank-subtracted  $A_{405}$  values for each standard (on the y axis) and the assigned concentration for each standard (along the x axis). The standard curve must meet the validation requirements. Most computers and calculators are capable of performing this calculation. An example of a typical standard curve is shown in Figure 1.

The  $\mu\text{g Eq/mL}$  concentration for each sample is calculated from the standard curve using linear regression analysis. Calculated values determined against the standard curve should be evaluated against the cut-off for positive reporting. See Interpretation below.

**Dilution Factor Adjustment.** The assigned CIC concentration has been determined assuming a 1:50 dilution of the specimen. If a higher dilution of the specimen was assayed, the user must multiply the calculated result by



the appropriate dilution factor. For example, if the specimen dilution assayed was 1:200, the calculated result must be multiplied by 4.

**Confirmation Test Calculation.** To confirm a positive result, the immune complex concentration [CIC] determined in the sample diluted in Confirmation Diluent is divided by the immune complex concentration measured in the sample diluted in the Complement Specimen Diluent to generate a ratio:

$$\text{Ratio} = \frac{[\text{CIC}] \text{ in Confirmation Diluent}}{[\text{CIC}] \text{ in Complement Specimen Diluent}}$$

## Validation

Determine the slope, y-intercept, and correlation coefficient of the derived best fit line. The values must be within the following ranges to qualify the assay.

Correlation coefficient (r):	Greater than 0.95
Slope (m):	0.022 to 0.056
y-intercept (b):	(-) 0.108 to (+) 0.238

## Interpretation


**Negative Results:** Values less than 4.0 µg Eq/mL are considered negative for significant levels of CIC.

**Positive Results:** Values greater than or equal to 4.0 µg Eq/mL are considered positive for significant levels of CIC.

**Confirmation Results:** If the ratio is less than 0.7, the positive CIC result is confirmed. In other words, greater than 30% reduction confirms a positive result.

Occasionally, positive specimens may not confirm. Nonconfirming specimens may be due to, among other reasons: (1) mishandled specimens (e.g. contaminated or heat-inactivated) or (2) specimens which contain autoantibodies to C1q. These specimens are not necessarily negative for CIC. The material causing the apparent false positive result may mask concomitantly occurring CIC which, if they were present alone, would otherwise give a confirmable positive CIC result.

**Figure 1**  
**Example of Standard Curve**



Sample	(A <sub>405</sub> )	µg Eq/mL
Standard A	0.09	0.2
Standard B	0.57	15.6
Standard C	1.05	31.1
Specimen 1	0.19	3.4
Specimen 2	0.82	23.7
Specimen 3	0.40	10.2
r = 1.00	m = 0.031	b = 0.085

## LIMITATIONS OF THE PROCEDURE

1. Heat inactivations of specimens may cause false positive results. Because this test measures aggregates of human IgG non-selectively, sample collection and processing must avoid conditions that promote aggregation of IgG.
2. The MicroVue CIC-C1q Enzyme Immunoassay has been used to test specimens collected as serum or as plasma in EDTA anticoagulant. Other anticoagulants have not been tested.

## EXPECTED VALUES

Circulating immune complexes (CIC) were measured in sera from 312 subjects using the MicroVue CIC-C1q Enzyme Immunoassay. One hundred six (106) sera were collected from normal, asymptomatic subjects. The average CIC concentration was 2.1 µg Eq/mL (S.D. = 1.9).

Specimens obtained from 206 patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or other disorders were tested using the MicroVue CIC-C1q Enzyme Immunoassay and another commercially available EIA kit. The overall agreement between the two test methods was 87%.

Within the above population, eighty-one (81) SLE patients and thirty-three (33) RA patients were tested. The two kits agreed for 82% of these specimens. These results are shown in Table 2.

**Table 2**  
**Comparative Data for Specific Patient Groups**

MicroVue Test Result	-	+	-	+
Alternative Test Result	-	+	+	-
RA Patients	18	9	3	3
SLE Patients	40	23	15	3
Other	0	90	2	0

## PERFORMANCE CHARACTERISTICS

### Accuracy

An immune complex standard prepared by the World Health Organization (WHO) using heat aggregated IgG was used to standardize the assay. To test the accuracy of the assay, five dilutions of the WHO standard were tested in triplicate in nine runs in the MicroVue kit. The assayed values were determined to be predictive of the expected standard concentrations (coefficient of determination = 0.97).

Forty-one (41) paired serum and plasma (EDTA anticoagulant) samples from SLE and RA patients were compared to demonstrate the suitability of plasma samples for the assay. No significant difference between the serum and plasma results was observed ( $\alpha = 0.05$ ).

## Reproducibility

Three serum samples and three standards were tested in nine assay runs in three different kit lots. Each standard was tested in triplicate within each assay run. Each serum specimen was run in a single well in each run; the average variation between each run for the specimens and standards is shown in Table 3 as interassay variation. The average variation within each run for the standards is shown in Table 3 as intraassay variation.

**Table 3**  
**Assay Reproducibility**

	Mean (Eq/mL)	Intraassay S.D. (% CV)	Interassay S.D. (% CV)
Specimen 1	30	NT	3.1 (10)
Specimen 2	7	NT	2.6 (37)
Specimen 3	0	NT	0.3 (N/A)
Standard 1	37	3.2 (9)	3.9 (11)
Standard 2	20	2.1 (10)	1.8 (9)
Standard 3	0	0.1 (N/A)	0.0 (N/A)

NT = not tested      N/A = not applicable

## Sensitivity

The analyte sensitivity of the MicroVue CIC-C1q Enzyme Immunoassay is 1.0  $\mu\text{g}$  Eq/mL.

## Specificity

One hundred six (106) serum and plasma specimens collected from normal, asymptomatic subjects were tested for CIC. The overall specificity of the assay was 94%.

## ASSISTANCE

To place an order or for technical support, please contact a Quidel representative at 800.874.1517 (in the U.S.) or 858.552.1100 (outside the U.S.), Monday through Friday, from 8:00 a.m. to 5:00 p.m., Eastern time. Orders may also be placed by fax at 740.592.9820. For e-mail support contact [customerservice@quidel.com](mailto:customerservice@quidel.com) or [technicalsupport@quidel.com](mailto:technicalsupport@quidel.com).

For services outside the U.S.A., please contact your local distributor. Additional information about Quidel, our products, and our distributors can be found on our website [quidel.com](http://quidel.com).

## REFERENCES

1. McDougal, J.S., McDuffie, F.C., Immune Complexes in Man: Detection and Clinical Significance, *Advances in Clinical Chemistry*, Vol. 24, p. 1, 1985.
2. Endo, L., Corman, L.C., Panush, R.S., Clinical Utility of Assays for Circulating Immune Complexes, *Medical Clinics of North America*, Vol. 69, No. 4, p. 623, July 1985.
3. Abrass, C.K., Nies, K.M., Louie, J.S., Border, W.A., Glasscock, R.J., Correlation and Predictive Accuracy of Circulating Immune Complexes with Disease Activity in Patients with Systemic Lupus Erythematosus, *Arthritis Rheum.*, Vol. 23, p. 273, 1980.
4. Duquesnoy, B., Circulating Immune Complexes and Complement in Rheumatoid Arthritis, *Ann. Biol. Clin.*, Vol. 42, p. 71, 1984.

5. Theofilopoulos, A.N., The Raji, Conglutinin, and Anti-C3 Assays for the Detection of Complement-Fixing Immune Complexes, *Methods in Enzymology*, Vol. 74, p. 511, 1981.
6. Agnello, V., Winchester, R.J., Kunkel, H.G., Precipitin Reactions of the C1q Component of Complement with Aggregated Gamma-Globulin and Immune Complexes in Gel Diffusion, *Immunology*, Vol. 19, p. 909, 1970.
7. Hack, C.E., Huijbregts, C.C., Paardekooper, J., Influence of Ionic Strength, EDTA Concentration, Endogenous C1q and Polyanions on the <sup>125</sup>I-C1q-Binding Test, *J. Immunol. Meth.*, Vol. 72, p. 197, 1984.
8. Richardson, J.H., Barkley, W.E., *Biosafety in Microbiological and Biomedical Laboratories*, p. 11-13, 1984.
9. Davidson, I., et al., *The Blood*, p. 1 20. in Cl. Davidson and J.B. Henry (ed.), Todd-Sanford Clinical Diagnosis, W.B. Saunders Co., Philadelphia, Pennsylvania, 1969.

MicroVue is a trademark of Quidel Corporation. Any other trademark contained in this document is the property of its respective owner and its use herein does not imply sponsorship or endorsement of any products or services.

**REF** A001 – MicroVue CIC-C1q EIA Kit

**IVD**



**EC REP**

MDSS GmbH  
Schiffgraben 41  
30175 Hannover,  
Germany



**Quidel Corporation**  
2005 East State Street, Suite 100  
Athens, OH 45701 USA  
[quidel.com](http://quidel.com)

**PIA001004EN00 (09/21)**

## GLOSSARY

---

**REF**

Catalogue number



CE mark of conformity

---

**EC REP**

Authorized Representative  
in the European Community

**LOT**

Batch code

---



Use by



Manufacturer

---



Temperature limitation



Intended use

---

**Rx ONLY**

Prescription use only



Consult e-labeling  
instructions for use

---



Biological risks

**IVD**

For *In Vitro* diagnostic use

---



Contains sufficient for 96 determinations

**CONT**

Contents/Contains

---

**CONTROL**

Control

---